Publicaciones en las que colabora con Maurizio Bendandi (20)

2021

  1. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

2017

  1. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Journal of Translational Medicine, Vol. 15, Núm. 1

  2. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy

    Oncotarget, Vol. 7, Núm. 4, pp. 4522-4530

  2. MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells

    Oncotarget, Vol. 7, Núm. 17, pp. 23182-23196

  3. Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy

    Biomaterials, Vol. 91, pp. 73-80

2015

  1. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia

    Biomaterials, Vol. 67, pp. 274-285

2007

  1. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

    Expert Opinion on Biological Therapy, Vol. 7, Núm. 5, pp. 599-615

  2. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions

    Journal of Investigative Dermatology, Vol. 127, Núm. 7, pp. 1673-1680

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

  2. El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones viráles crónicas

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 1, pp. 77-96

  3. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena

    Clinical Cancer Research

2005

  1. Critical appraisal of the current status of dendritic cell based therapy

    Inmunologia, Vol. 24, Núm. 1, pp. 23-32

  2. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas

    Journal of Clinical Oncology, Vol. 23, Núm. 5, pp. 999-1010

2004

  1. A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients

    Bone Marrow Transplantation, Vol. 33, Núm. 5, pp. 499-502

  2. Inmunoterapia activa en el tratamiento de neoplasias hematológicas

    Anales del sistema sanitario de Navarra, Vol. 27, Núm. 1, pp. 45-62

  3. Past, present and future of anti-idiotype vaccination

    Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23

2003

  1. Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies

    Clinical Cancer Research, Vol. 9, Núm. 15, pp. 5454-5464

  2. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases

    Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181

2002

  1. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells: Exploiting cross-priming

    Experimental Hematology, Vol. 30, Núm. 12, pp. 1355-1364